| Literature DB >> 24586792 |
Molly A Trecker1, Cheryl Waldner2, Ann Jolly3, Mingmin Liao4, Weiming Gu5, Jo-Anne R Dillon6.
Abstract
Globally, incidence of Neisseria gonorrhoeae infection is once again the highest of the bacterial sexually transmitted infections. The bacterium can produce serious complications in those infected, and emerging resistance to third generation cephalosporins could usher in an era of potentially untreatable gonorrhea. This research aimed to identify risk factors for antibiotic resistant gonorrhea infection among clients at a Shanghai sexually transmitted infection clinic over two time periods, 2004-2005 and 2008-2011. Demographic and risk factor behavior data, and biological samples for antimicrobial resistance analysis, were collected. Statistical models were built to identify risk factors associated with probable resistance to ceftriaxone and resistance to penicillin and tetracycline. High levels of ciprofloxacin resistance (98%) in our sample precluded examining its risk factors; all isolates were susceptible to spectinomycin. Overall (P<0.001), chromosomal (P<0.001), and plasmid-mediated (P = 0.01) penicillin resistance decreased from the first to second period of the study. For tetracycline, chromosomal resistance decreased (P = 0.01) and plasmid-mediated resistance increased (P<0.001) between the first and second periods of study. In multi-level multivariable regression models, male gender (P = 0.03) and older age (P = 0.01) were associated with increased minimum inhibitory concentrations to ceftriaxone. Male gender (P = 0.03) and alcohol use (P = 0.02) were associated with increased odds of overall tetracycline resistance. Male gender was associated with increased odds of chromosomally-mediated tetracycline resistance (P = 0.04), and alcohol use was associated with increased odds of plasmid-mediated tetracycline resistance (P = 0.02). Additionally, individuals in middle-salary categories were found to have lower odds of plasmid-mediated resistance to tetracycline compared with those in the lowest salary category (P≤0.02). This study is one of the first to use multilevel analysis to consider the association between risk factors for gonorrhea infections and mechanisms of resistance to individual antibiotics. Such information is urgently needed to combat the growing threat of untreatable gonorrhea.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24586792 PMCID: PMC3929748 DOI: 10.1371/journal.pone.0089458
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Selected demographic characteristics and risk behaviors of a sample of clients from the Shanghai Sexually Transmitted Infection and Skin Disease Hospital (n = 384).
| Mean (SD), Median (IQR), or N (%) | |||
| Variable | Phase 1 (n = 189) | Phase 2 (n = 195) | Overall |
| Mean age (years) | 34.5 (10.0) | 36.7 (12.1) | 35.6 (11.2) |
| Median salary (Yuan) | 2500 (1200,4500) | 3500 (2000,5500) | 3000 (1500,5000) |
| Gender | |||
|
| 156 (82.5) | 180 (92.3) | 336 (87.5) |
|
| 33 (17.5) | 15 (7.7) | 48 (12.5) |
| Education level | |||
|
| 5 (2.6) | 2 (1.0) | 7 (1.8) |
|
| 61 (32.2) | 59 (30.3) | 120 (31.3) |
|
| 63 (33.3) | 49 (25.1) | 112 (29.2) |
|
| 60 (31.7) | 85 (43.6) | 145 (37.8) |
| Previous STI history | 69 (36.5) | 70 (35.9) | 139 (36.2) |
| Previous bacterial STI | 31 (16.4) | 62 (31.8) | 93 (24.2) |
| Wash genitals before or after sex | 121 (64.0) | 165 (84.6) | 286(74.5) |
| Take OTC ABX ever | 17 (9.0) | 37 (19.0) | 54(14.1) |
| Use alcohol during sex ever4 | 76 (40.2) | 67 (34.4) | 143(37.3) |
| Use drugs during sex ever5 | 10 (5.3) | 18 (9.2) | 28(7.3) |
| Number of partners in previous 3 months6 | |||
|
| 82 (43.4) | 68 (34.9) | 150 (39.1) |
|
| 50 (26.5) | 66 (33.8) | 116 (30.2) |
|
| 45 (23.8) | 49 (25.1) | 94 (24.5) |
*Significant difference between phases at p<0.001.
Significant difference between phases at p = 0.004.
6 missing 211 missing 374 missing 41 missing 52 missing 624 missing.
MICs of 384 N. gonorrhoeae isolates from Shanghai to ceftriaxone, ciprofloxacin, spectinomycin, penicillin, and tetracycline.
| MIC N (cumulative %) | |||||||||||||||
| Antibiotic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3 (0.8) | 24 (7.0) | 66 (24.2) | 133 (58.9) | 116 (89.1) | 40 (99.5) | 2 (100) | – | – | – | – | – | – | – | – |
|
| – | – | 1 (0.3) | – | 1 (0.5) | – | – | 4 (1.6) | 10 (4.2) | 40 (14.6) | 69 (32.6) | 121 (64.2) | 103 (91.1) | 32 (99.5) | 2 (100) |
|
| – | – | – | – | – | – | – | – | – | 2 (0.5) | 17 (4.9) | 44 (16.7) | 159 (47.8) | 150 (96.9) | 12 (100) |
|
| – | – | – | – | – | 1 (0.3) | 7 (2.1) | 12 (5.2) | 32 (13.5) | 67 (31.0) | 48 (43.5) | 22 (49.2) | 9 (51.6) | 18 (56.3) | 168 (100) |
|
| – | – | – | – | 4 (1.0) | 20 (6.3) | 31 (14.3) | 35 (23.4) | 84 (45.3) | 59 (60.7) | 23 (66.7) | 9 (69.0) | 26 (75.8) | 40 (86.2) | 53 (100) |
N = 383 for ciprofloxacin.
Distribution of MICs for 384 N. gonorrhoeae isolates to ceftriaxone, ciprofloxacin, spectinomycin, penicillin, and tetracycline. Number of isolates and cumulative percent for each MIC breakpoint are shown for each antibiotic.
Prevalence of resistance or reduced susceptibility to ceftriaxone, penicillin, and tetracycline in a sample of clients from the Shanghai Sexually Transmitted Infection and Skin Disease Hospital.
| Phase 1 N (%) | Phase 2 N (%) | Overall | |
|
| 189 | 195 | 384 |
|
| |||
|
| 143 (75.7) | 148 (75.9) | 291 (75.8) |
|
| 21 (11.1) | 21 (10.8) | 42 (10.9) |
|
| |||
|
| 14 (7.4) | 38 (19.5) | 52 (13.5) |
|
| 175 (92.5) | 157 (80.5) | 332 (86.5) |
|
| 78 (41.3) | 61 (31.3) | 139 (36.2) |
|
| 97 (51.3) | 96 (49.2) | 193 (50.3) |
|
| |||
|
| 90 (47.6) | 84 (43.1) | 174 (45.3) |
|
| 99 (52.4) | 111 (56.9) | 210 (54.7) |
|
| 62 (32.8) | 29 (14.9) | 91 (23.7) |
|
| 37 (19.6) | 82 (42.1) | 119 (31.0) |
WHO 2012.
*CLSI 2009;
Phases 1 and 2 combined.
The range of MIC values for each antibiotic were as follows: ceftriaxone 0.004–0.25, penicillin 0.125–64, tetracycline 0.06–64.
Results of multivariable analysis for reduced susceptibility and probable resistance to ceftriaxone (odds ratios (OR) and 95% confidence intervals (95% CI)).
| a. | Ceftriaxone reduced susceptibility (MIC≥0.03 µg/mL) (n = 378) | |||||
| Variable | OR | p-value | 95% CI | |||
|
|
|
|
| |||
| Age (4 df) | 0.58 | |||||
| 14–26 years | Reference category | |||||
| 27–31 years | 0.72 | 0.40 | 0.34–1.53 | |||
| 32–37 years | 0.63 | 0.23 | 0.29–1.34 | |||
| 38–45 years | 0.98 | 0.95 | 0.45–2.14 | |||
| 46–83 years | 0.62 | 0.21 | 0.29–1.32 | |||
|
|
| |||||
|
|
| |||||
|
|
|
|
| |||
| Male : Female | 1.64 | 0.45 | 0.46–5.84 | |||
|
|
| |||||
| 14–26 years | Reference category | |||||
| 27–31 years | 1.18 | 0.80 | 0.35–3.83 | |||
| 32–37 years | 0.79 | 0.73 | 0.21–2.99 | |||
| 38–45 years | 1.51 | 0.47 | 0.50–4.57 | |||
|
|
|
|
| |||
|
|
| |||||
| Do not take OTC antibiotics | Reference category | |||||
| Take OTC antibiotics | 1.64 | 0.24 | 0.71–3.82 | |||
|
|
|
|
| |||
|
|
| |||||
Final models for reduced susceptibility to ceftriaxone with significant predictors shown in bold.
Results of multivariable analysis of factors associated with resistance to penicillin based on MIC classification and type of penicillin resistance based on molecular data (odds ratios (OR) and 95% confidence intervals (95% CI)).
| Penicillin Resistance (n = 378) | Penicillin Resistance Type (n = 378) | ||||||||
|
|
| ||||||||
| Variable | OR | p-value | 95% CI | OR | p-value | 95% CI | OR | p-value | 95% CI |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
| |||||||||
Phase of study was the only significant predictor of penicillin outcomes.
Results of multivariable analysis for overall and type of tetracycline resistance (resistance (odds ratios (OR) and 95% confidence intervals (95% CI)).
| a. | Tetracycline Resistance (n = 376) | ||||||||||
| Variable | OR | p-value | 95% CI | ||||||||
|
|
|
|
| ||||||||
|
|
| ||||||||||
| Less than primary or no education | Reference category | ||||||||||
| Primary/middle school | 2.23 | 0.35 | 0.44–10.39 | ||||||||
| High school | 1.02 | 0.98 | 0.21–5.01 | ||||||||
| Above high school | 0.76 | 0.74 | 0.15–3.78 | ||||||||
|
|
|
|
| ||||||||
|
| |||||||||||
|
|
| ||||||||||
|
|
| ||||||||||
|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
| |||||
|
|
|
|
| 1.18 | 0.70 | 0.52–2.66 | |||||
|
| 1.68 | 0.07 | 0.96–2.93 |
|
|
| |||||
|
|
| ||||||||||
| <1300 Yuan | Reference category | ||||||||||
| 1300–2000 Yuan | 0.78 | 0.57 | 0.33–1.84 | 0.99 | 0.98 | 0.46–2.16 | |||||
|
| 0.78 | 0.54 | 0.35–1.72 |
|
|
| |||||
|
| 0.77 | 0.55 | 0.33–1.81 |
|
|
| |||||
| 6000–200000 Yuan | 0.57 | 0.24 | 0.22–1.47 | 0.96 | 0.91 | 0.42–2.16 | |||||
|
| |||||||||||
|
| |||||||||||
Final models for tetracycline outcomes with significant predictors shown in bold.